by Minomic | Apr 20, 2021
Sydney, April 20, 2021: GloriousMed Biomedical Group Co., Ltd (“GloriousMed”) and Minomic International Ltd (“Minomic”) of Australia officially executed the agreement, which formally launched the commercialization of MiCheck® Prostate, a...
by Minomic | Mar 17, 2021
We are delighted to report positive results from our collaborative research evaluating Minomic’s GPC-1 antibody for the detection of pancreatic cancer (one of the deadliest cancers) in collaboration with BARD1 Life Sciences Ltd EXO-NET exosome capture technology....
by Minomic | Feb 11, 2021
At Minomic, we are proud to be part of the NSW Going Global Export Program, a NSW Government funded export assistance package, designed to boost NSW exports and unlock international markets for sustainable businesses following the impacts of COVID-19, the bushfires...
by Minomic | May 12, 2020
Minomic International Ltd (Minomic) is pleased to report publication of our back-to-back papers covering the recent MiCheck® prospective trial in the journal Urologic Oncology. The two papers, “A comparison of prostate health index, total PSA, %free PSA, and proPSA in...
by Minomic | May 21, 2019
Click here to watch the interview with Brad Walsh, CEO of Minomic International Ltd. The interview is about: – The perspectives on leadership – Best aspects of being involved in the health sector – Important traits a leader should have in the sector...
by Minomic | Feb 14, 2019
Agreement enables early access to the MiCheck® Prostate Cancer Test for US Clinicians & Patients Read Chinese version of the news “Minomic Signs Agreement with US Pathology Laboratory” here February 14, 2019: [Sydney] Minomic International Ltd is...
